Multiple BRAF-targeted therapies (i.e., vemurafenib, dabrafenib, and encorafenib) [2] have been designed to specifically treat melanomas of this genotype by limiting the mutation’s ability to affect downstream MAP kinase signaling. The gene discussed is BRAF; the disease is melanoma.